A Phase Ib/II Trial to Evaluate Safety, Tolerability and Efficacy of Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Latest Information Update: 25 Sep 2023
At a glance
- Drugs AK 01 (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 20 Sep 2023 Planned End Date changed from 25 May 2024 to 30 Jun 2025.
- 20 Sep 2023 Planned primary completion date changed from 25 May 2024 to 30 Jun 2025.
- 31 May 2023 Status changed from recruiting to active, no longer recruiting.